448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Oncology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdu331.8PMID 28174858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries

  2020cites this paper
• Unveiling changes in the landscape of patient populations in cancer early drug development

  2016cites this paper
• NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

  2016cites this paper
• “ALKoma” in NSCLC- Optimizing Diagnosis and Treatment Strategies

  2016cites this paper
• Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

  2015cites this paper
• Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

  2015cites this paper
• Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

  2015cites this paper
• Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

  2015cites this paper
• New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer

  2015cites this paper